Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

NCT00983853 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
HIV Infections

Interventions

DRUG: telaprevir or matching placebo
DRUG: telaprevir or matching placebo
BIOLOGICAL: peginterferon alfa-2a
DRUG: ribavirin (fixed dose)
DRUG: ribavirin (weight-based dose)

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]